Evaluation of the effectiveness and safety of chemoprophylaxis for vertical HIV transmission, by using the regimens of monotherapy and highly active antiretroviral therapy



Cite item

Full Text

Abstract

The study including 69 pregnant women diagnosed as having HIV infection who received chemoprophylaxis for vertical HIV infection evaluated the effectiveness and safety of the regimens of monotherapy and highly active antiretroviral therapy (HAART) used during pregnancy. There was a significant reduction in the levels of HIV RNA and an increase in the CD4 lymphocyte count in the patients receiving both chemoprophylaxis regimens. The efficiency of HAART regimens to prevent vertical HIV transmission was significantly higher than that of monoprophylaxis. The use of antiretroviral drugs was safe as monotherapy and in the HAART regimens during pregnancy.

About the authors

D S Konnov

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Email: kodanila@yandex.ru
Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

M D Goliusova

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

V V Konnov

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

N V Kozyrina

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

N N Ladnaya

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

O G Yurin

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

References

  1. Гепатотоксичность у больных ВИЧ-инфекцией, получавших ВААРТ / Канестри В. Г., Кравченко А. В., Ганкина Н. Ю. и др. - М., 2006.
  2. Cooper E., Charurat M., Mofenson L. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission // J. Acquir Immune Defic. Syndr. - 2002. - Vol. 29, N 5. - P. 484-494. http://www.nebi.nlm.nih.gov/pubmed/11981365].
  3. DHHS Guidelines, May 4, 2006, http/:AIDSinfo.nih.gov
  4. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. // Clin. Infect. Dis. - 2005. - Vol. 40. - P. 458-465.
  5. Francis M., Nicholson J., Autran B., Janossy G. T-cell subset counting and fight against AIDS: Reflection over a 20-years struggle // Cytometry. - 2002. - Vol. 50. - P. 39-45.
  6. Garcia P. M., Kalish L. A., Pitt J. et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission // N. Engl. J. Med. - 1999. - Vol. 341, N 6. - P. 394-402.
  7. IAS-USA Guidelines. // J. A. M. A. - 2004. - Vol. 292, N 2.
  8. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study // AIDS. - 1999. - Vol. 13, N 11. - P. 1377-1385. http://www.ncbi.nlm.nih.gov/pubmed/10449292.
  9. Mayaux M.-J., Blanche S., Rouzioux C. et al. Maternal factors associated with perinatal HIV-1 transmission: the French cohort study. Seven years of follow-up observation // J. AIDS. - 1995. - Vol. 8. - P. 188-194.
  10. Mofensen L., Steihm E. R., Lambert J. et al. Efficacy of zidovudine in reducing perinatal HIV-1 transmission in HIV-1-infected women with advanced disease // 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. - Toronto, 1997. - P. 11-13.
  11. Mofenson L. M., Lambert J. S., Stiehm E. R. et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team // N. Engl. J. Med. - 1999. - Vol. 341, N 6. - P. 385-393. http://www.ncbi.nlm.nih.gov/pubmed/10432323.
  12. Nielsen K. A. MPH preventing mother-to-child transmission of HIV worldwide: Successes, challenges, and concerns medscape // HIV/AIDS. - 2004. - Vol. 10, N 2. - P. 4-9.
  13. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009; http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
  14. Rogers M. F., Jaffe H. W. Reducing the risk of maternal-infant transmission of HIV: A door is opened // N. Engl. J. Med. - 1994. - Vol. 331. - P. 1222-1223.
  15. Shaffer N., Chuachoowong R., Mock P. A. et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial // Lancet. - 1999. - Vol. 353, N 9155. - P. 773-780.
  16. Thorne C., Newell M. European Collaborative Study. Pregnancy outcome in ART-treated HIV-infected women in Europe // Program and Abstracts of the 11-th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California. - San Francisco, 2004. - Abstr. 98.
  17. Women and Infants Transmission Study (WITS). // J. Acquir. Immune Defic. Syndr. - 2002. - Vol. 29. - P. 484.

Copyright (c) 2010 Eco-vector



Свидетельство о регистрации СМИ № 014448 от 08.02.1996 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). 
Свидетельство о регистрации СМИ ЭЛ № ФС 77 - 80652 от 15.03.2021 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies